JP2022541013A5 - - Google Patents
Info
- Publication number
- JP2022541013A5 JP2022541013A5 JP2022502212A JP2022502212A JP2022541013A5 JP 2022541013 A5 JP2022541013 A5 JP 2022541013A5 JP 2022502212 A JP2022502212 A JP 2022502212A JP 2022502212 A JP2022502212 A JP 2022502212A JP 2022541013 A5 JP2022541013 A5 JP 2022541013A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- lxr
- agonist
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962874433P | 2019-07-15 | 2019-07-15 | |
| US62/874,433 | 2019-07-15 | ||
| US201962939138P | 2019-11-22 | 2019-11-22 | |
| US62/939,138 | 2019-11-22 | ||
| PCT/IB2020/056584 WO2021009664A1 (en) | 2019-07-15 | 2020-07-13 | Methods for treating meibomian gland dysfunction with liver x receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022541013A JP2022541013A (ja) | 2022-09-21 |
| JP2022541013A5 true JP2022541013A5 (https=) | 2023-07-20 |
Family
ID=71728831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502212A Pending JP2022541013A (ja) | 2019-07-15 | 2020-07-13 | 肝臓ｘ受容体アゴニストでマイボーム腺機能不全を治療するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220257596A1 (https=) |
| EP (1) | EP3999055A1 (https=) |
| JP (1) | JP2022541013A (https=) |
| CN (1) | CN114126618A (https=) |
| WO (1) | WO2021009664A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024518128A (ja) * | 2021-05-20 | 2024-04-24 | ノバルティス アーゲー | ３－（（３－（４－（２－（イソブチルスルホニル）フェノキシ）－３－（トリフルオロメチル）フェニル）－１，２，４－オキサジアゾール－５－イル）メチル）－５，５－ジメチル－１－（２－モルホリノエチル）イミダゾリジン－２，４－ジオンの製剤 |
| CN115607547A (zh) * | 2021-07-14 | 2023-01-17 | 厦门大学 | 一种睑板腺功能障碍动物模型的造模药物、构建方法与应用 |
| CN119732940A (zh) * | 2024-12-27 | 2025-04-01 | 重庆医科大学 | 肝x受体激动剂在改善和/或治疗抑郁样行为中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6316503B1 (en) | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
| WO2002024632A2 (en) | 2000-09-18 | 2002-03-28 | Glaxo Group Limited | Substituted aminopropoxyaryl derivatives useful as agonists for lxr |
| US7560586B2 (en) | 2002-03-27 | 2009-07-14 | Smithkline Beecham Corporation | Acid and ester compounds and methods of using the same |
| WO2005023196A2 (en) | 2003-09-03 | 2005-03-17 | Smithkline Beecham Corporation | Compounds and methods |
| JP4809338B2 (ja) | 2004-06-28 | 2011-11-09 | エフ．ホフマン−ラ ロシュ アーゲー | 新規なヘキサフルオロイソプロパノール誘導体 |
| EP1773781A2 (en) | 2004-08-03 | 2007-04-18 | Wyeth | Indazoles useful in treating cardiovascular diseases |
| US20060178398A1 (en) | 2004-09-16 | 2006-08-10 | Adams Alan D | Therapeutic compounds for treating dyslipidemic conditions |
| JP2008526841A (ja) | 2005-01-10 | 2008-07-24 | アストラゼネカ アクチボラグ | 肝臓ｘ受容体調節因子としてのイソチアゾール−３（２ｈ）−オン１，１−ジオキシドのアニリン系誘導体 |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| KR101676704B1 (ko) | 2009-05-28 | 2016-11-16 | 엑셀리시스 페이턴트 컴퍼니 엘엘씨 | Ｌｘｒ 조절자 |
| SG10201607345YA (en) | 2012-03-02 | 2016-11-29 | Ralexar Therapeutics Inc | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
| WO2013138568A1 (en) | 2012-03-16 | 2013-09-19 | Vitae Pharmaceuticals, Inc. | Liver x reception modulators |
| WO2015187840A2 (en) * | 2014-06-03 | 2015-12-10 | Duke University | Methods and formulations for treatment of ocular disorders |
| BR112017002260A2 (pt) | 2014-08-07 | 2017-11-21 | Vitae Pharmaceuticals Inc | derivados de piperazina como moduladores do receptor x do fígado |
| WO2017083219A1 (en) | 2015-11-12 | 2017-05-18 | Merck Sharp & Dohme Corp. | Bispiperidinyl derivatives as liver x receptor beta agonists, compositions, and their use |
| EP3373935B1 (en) | 2015-11-12 | 2021-09-01 | Merck Sharp & Dohme Corp. | Cyanopyridine derivatives as liver x receptor beta agonists, compositions, and their use |
| AU2018312349A1 (en) * | 2017-08-01 | 2020-02-06 | Theravance Biopharma R&D Ip, Llc | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors |
| IL315313A (en) * | 2018-08-24 | 2024-10-01 | Xeniopro GmbH | Aromatic molecules for use in the treatment of pathological conditions |
| JP2022514257A (ja) * | 2018-12-13 | 2022-02-10 | アイノス，インコーポレイテッド | ドライアイ疾患の治療のための局所点眼製剤におけるｌｘｒアゴニスト |
-
2020
- 2020-07-13 EP EP20743349.1A patent/EP3999055A1/en not_active Withdrawn
- 2020-07-13 CN CN202080050172.3A patent/CN114126618A/zh active Pending
- 2020-07-13 JP JP2022502212A patent/JP2022541013A/ja active Pending
- 2020-07-13 WO PCT/IB2020/056584 patent/WO2021009664A1/en not_active Ceased
- 2020-07-13 US US17/625,201 patent/US20220257596A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104066731B (zh) | 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类 | |
| JP6434416B2 (ja) | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 | |
| US7919484B2 (en) | Combination therapy | |
| CN107223125B (zh) | sGC刺激剂 | |
| JP2005536475A5 (https=) | ||
| JP2022541013A5 (https=) | ||
| JP5780430B2 (ja) | 勃起不全の処置用のＰＤＥ５阻害剤と組み合わせたｓＧＣ刺激剤またはｓＧＣ活性化剤 | |
| JP2003516363A (ja) | 勃起機能不全の処置のためのホスホジエステラーゼインヒビターの経粘膜投与 | |
| JP7101688B2 (ja) | ｓＧＣ刺激薬とミネラルコルチコイド受容体拮抗薬とを含む組み合わせ | |
| JP2023507094A (ja) | Ｃｇｒｐ阻害剤の鼻腔内医薬組成物 | |
| JP2005519851A (ja) | 早漏の治療のためのホスホジエステラーゼインヒビターの投与 | |
| JP2003525845A (ja) | 勃起機能不全の処置のためのホスホジエステラーゼインヒビターの局所投与 | |
| WO2020259528A1 (zh) | 治疗特发性肺纤维化的方法 | |
| JP2023504415A5 (https=) | ||
| KR20050042154A (ko) | 통증의 치료에 사용하기 위한 알파-2-델타 리간드와 ｐｄｅｖ 억제제의 상승작용 조합물 | |
| JP2003503360A (ja) | 炎症性疾患の処置のための併用療法 | |
| JP6849618B2 (ja) | 中性エンドペプチダーゼの阻害剤（ＮＥＰ阻害剤）および／またはアンジオテンシンＩＩ拮抗薬と組み合わせた可溶性グアニル酸シクラーゼ（ｓＧＣ）の刺激薬および／または活性化薬ならびにその使用 | |
| CN115485027A (zh) | 冠状病毒感染引起的化学感觉功能障碍的治疗 | |
| JP2005505539A (ja) | パーキンソン病の治療のためのｃｂ１受容体アンタゴニストと、脳のドーパミン作用性神経伝達を活性化する製品を含む組成物 | |
| JP2002053493A (ja) | 全身性エリテマトーデスおよび炎症性腸疾患を治療するための成長ホルモン分泌促進物質の使用 | |
| JP2008514709A (ja) | 眼科疾患を治療するための組成物および方法 | |
| JP2005513060A (ja) | 選択的ｐｄｅ５阻害剤の新規使用 | |
| JP2024505509A (ja) | Ｃｇｒｐ阻害薬の医薬組成物およびそれらを使用する方法 | |
| US20050014762A1 (en) | Combination | |
| US12116341B1 (en) | Pharmaceutical compounds, pharmaceutical compositions, and methods of treating asthma and other disorders |